Biofrontera Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 4/3/2026)
| Balance Sheet | Total Assets | 28,564,000.00 | ROE | 36.69 % |
| Balance Sheet | Total Equity | 10,480,000.00 | ROA | -36.89 % |
| Cashflow | Capital Expenditures | -2,000.00 | P/FCF | -2.62 |
| Cashflow | Free Cash Flow | -13,363,000.00 | – | – |
| Cashflow | Operating Cash Flow | -13,361,000.00 | P/CF | -2.62 |
| Income | Earnings per Share (diluted) | -0.90 | Div. Yield | – |
| Income | Net Income | -10,536,000.00 | P/E | -3.34 |
| Income | Shares Outstanding | 11,648,300.00 | P/B | 3.35 |
| Income | Total Revenue | 41,705,000.00 | P/S | 0.84 |
Ratios calculated on: 10/14/2026
Company Description
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of mild to moderate acne. The company offers its products primarily in the United States, Europe, and Israel. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.biofrontera.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more